Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.65 |
| ▸ | POLB | P06746 | 3/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | EGFR | P00533 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12464040 | 0.83 | KDM4E (0.69) | KDM4EALDH1A1KMT2APOLBSMN1; SMN2 | |
| SCHEMBL547543 | 0.82 | KDM4E (1.00) | KDM4EALDH1A1KMT2APOLBSMN1; SMN2 | |
| SCHEMBL8694831 | 0.80 | ALDH1A1 (0.71) | ALDH1A1KMT2ASMN1; SMN2MEN1LMNA | |
| SCHEMBL9978110 | 0.79 | KDM4E (0.70) | KDM4EALDH1A1KMT2APOLBSMN1; SMN2 | |
| SCHEMBL5446301 | 0.79 | SMN1; SMN2 (0.68) | KDM4EALDH1A1KMT2APOLBSMN1; SMN2 | |
| SCHEMBL15986425 | 0.79 | KDM4E (0.70) | KDM4EALDH1A1KMT2APOLBSMN1; SMN2 | |
| Sulfapyridine SCHEMBL44219 | 0.78 | SMN1; SMN2 (1.00) | KDM4EALDH1A1KMT2APOLBSMN1; SMN2 | |
| Sulfapyridine SCHEMBL29438089 | 0.78 | SMN1; SMN2 (1.00) | KDM4EALDH1A1KMT2APOLBSMN1; SMN2 | |
| SCHEMBL10031583 | 0.78 | KDM4E (0.77) | KDM4EALDH1A1KMT2APOLBSMN1; SMN2 | |
| SCHEMBL1667129 | 0.77 | KDM4E (0.75) | KDM4EALDH1A1KMT2APOLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9150561-B2 | Thiazole derivatives and use thereof | MERCK SERONO S.A. (CH) | 2015-10-06 | — | — | US | disclosed |
| US-20140228365-A1 | THIAZOLE DERIVATIVES AND USE THEREOF | MERCK SERONO S.A. (CH) | 2014-08-14 | — | — | US | disclosed |
| US-8802861-B2 | Thiazole derivatives and use thereof | MERCK SERONO SA (CH) | 2014-08-12 | — | — | US | disclosed |
| EP-1709019-B1 | THIAZOLE DERIVATIVES AND USE THEREOF | APPLIED RESEARCH SYSTEMS (AN) | 2007-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228365-A1 | THIAZOLE DERIVATIVES AND USE THEREOF | PF4, TEC, PDGFRB | KDM4E 4820/4885ALDH1A1 234/4885KMT2A 4760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.